JP2015529641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529641A5 JP2015529641A5 JP2015521849A JP2015521849A JP2015529641A5 JP 2015529641 A5 JP2015529641 A5 JP 2015529641A5 JP 2015521849 A JP2015521849 A JP 2015521849A JP 2015521849 A JP2015521849 A JP 2015521849A JP 2015529641 A5 JP2015529641 A5 JP 2015529641A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- tumor
- variable region
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 15
- 230000004927 fusion Effects 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 102000015735 Beta-catenin Human genes 0.000 claims description 6
- 108060000903 Beta-catenin Proteins 0.000 claims description 6
- 230000004614 tumor growth Effects 0.000 claims description 6
- 102000037126 Leucine-rich repeat-containing G-protein-coupled receptors Human genes 0.000 claims description 5
- 108091006332 Leucine-rich repeat-containing G-protein-coupled receptors Proteins 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000054144 human RSPO3 Human genes 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000013074 reference sample Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029640 digestive system melanoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
- 101000825949 Homo sapiens R-spondin-2 Proteins 0.000 description 2
- 101150116752 Rspo3 gene Proteins 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 101001063463 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 4 Proteins 0.000 description 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 1
- 101000981765 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 6 Proteins 0.000 description 1
- 102100031035 Leucine-rich repeat-containing G-protein coupled receptor 4 Human genes 0.000 description 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 description 1
- 102100024140 Leucine-rich repeat-containing G-protein coupled receptor 6 Human genes 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671421P | 2012-07-13 | 2012-07-13 | |
| US61/671,421 | 2012-07-13 | ||
| US201361753184P | 2013-01-16 | 2013-01-16 | |
| US61/753,184 | 2013-01-16 | ||
| US201361789156P | 2013-03-15 | 2013-03-15 | |
| US61/789,156 | 2013-03-15 | ||
| US201361826747P | 2013-05-23 | 2013-05-23 | |
| US61/826,747 | 2013-05-23 | ||
| PCT/US2013/050300 WO2014012007A2 (en) | 2012-07-13 | 2013-07-12 | Rspo3 binding agents and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015529641A JP2015529641A (ja) | 2015-10-08 |
| JP2015529641A5 true JP2015529641A5 (OSRAM) | 2016-09-01 |
| JP6335896B2 JP6335896B2 (ja) | 2018-05-30 |
Family
ID=49914164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521849A Expired - Fee Related JP6335896B2 (ja) | 2012-07-13 | 2013-07-12 | Ｒｓｐｏ３結合剤およびその使用法 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9181333B2 (OSRAM) |
| EP (1) | EP2872175A4 (OSRAM) |
| JP (1) | JP6335896B2 (OSRAM) |
| KR (1) | KR20150036603A (OSRAM) |
| CN (1) | CN104854132A (OSRAM) |
| AU (1) | AU2013289990B2 (OSRAM) |
| BR (1) | BR112015000776A2 (OSRAM) |
| CA (1) | CA2878868A1 (OSRAM) |
| CL (1) | CL2015000097A1 (OSRAM) |
| EA (1) | EA032038B1 (OSRAM) |
| EC (1) | ECSP15005280A (OSRAM) |
| HK (1) | HK1208687A1 (OSRAM) |
| IL (1) | IL236617A0 (OSRAM) |
| IN (1) | IN2015KN00350A (OSRAM) |
| MX (1) | MX2015000565A (OSRAM) |
| NI (1) | NI201500002A (OSRAM) |
| NZ (1) | NZ704269A (OSRAM) |
| PE (1) | PE20150360A1 (OSRAM) |
| PH (1) | PH12015500084A1 (OSRAM) |
| SG (1) | SG11201500233PA (OSRAM) |
| TW (2) | TWI636061B (OSRAM) |
| UA (1) | UA117659C2 (OSRAM) |
| WO (1) | WO2014012007A2 (OSRAM) |
| ZA (1) | ZA201500872B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| JP5931336B2 (ja) | 2007-07-02 | 2016-06-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんを処置および診断するための組成物および方法 |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US9260519B2 (en) | 2011-06-17 | 2016-02-16 | President And Fellows Of Harvard College | Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer |
| CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
| CA2878868A1 (en) | 2012-07-13 | 2014-01-16 | Austin L. Gurney | Rspo3 binding agents and uses thereof |
| BR112016008477A2 (pt) * | 2013-10-18 | 2017-10-03 | Genentech Inc | Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo |
| KR20170029490A (ko) | 2014-07-11 | 2017-03-15 | 제넨테크, 인크. | 노치 경로 억제 |
| EP3193935A4 (en) | 2014-09-16 | 2018-03-21 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| MA41123A (fr) * | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
| WO2017040660A1 (en) * | 2015-08-31 | 2017-03-09 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| CN106913880B (zh) * | 2015-12-24 | 2021-02-12 | 上海交通大学 | 一种含有rspo1的靶向给药系统及其制备与应用 |
| CN105925576B (zh) * | 2016-03-24 | 2018-04-20 | 嘉兴市第一医院 | 针对哺乳动物R‑Spondin3基因靶点的小干扰RNA、短发卡RNA及载体和应用 |
| EP3865511A1 (en) | 2016-04-14 | 2021-08-18 | F. Hoffmann-La Roche AG | Anti-rspo3 antibodies and methods of use |
| WO2018035210A1 (en) * | 2016-08-17 | 2018-02-22 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with an rspo antagonist |
| EP3720492A4 (en) * | 2017-12-07 | 2021-12-08 | National Health Research Institutes | ANTI-RSPO3 ANTIBODIES |
| CN110339364B (zh) * | 2018-04-02 | 2021-02-12 | 上海邦耀生物科技有限公司 | Lgr4/rspo阻断剂与抗免疫检查点抑制剂联合用于肿瘤的免疫治疗 |
| CN110467663B (zh) * | 2019-06-18 | 2022-05-10 | 华南农业大学 | Rspo3基因在母猪卵巢颗粒细胞中的应用 |
| EP4076497A1 (en) * | 2019-12-19 | 2022-10-26 | Deutsches Krebsforschungszentrum | Leukemia treatment |
| KR102554222B1 (ko) * | 2023-03-21 | 2023-07-11 | 순천향대학교 산학협력단 | 신규한 항-인간 알스폰딘3 항체 및 이의 용도 |
| CN116769030B (zh) * | 2023-08-21 | 2023-10-20 | 成都大熊猫繁育研究基地 | 一种大熊猫松弛素3单克隆抗体及其杂交瘤细胞株和应用 |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US20070124581A1 (en) | 1992-05-17 | 2007-05-31 | Reena Khare | Cell adhesion and extracellular matrix proteins |
| CA2288343A1 (en) | 1997-04-25 | 1998-11-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| JP2001517441A (ja) | 1997-09-24 | 2001-10-09 | メルク エンド カムパニー インコーポレーテッド | Ｇタンパク質共役糖タンパク質ホルモン受容体ｈｇ３８ |
| US20020065394A1 (en) | 1998-03-18 | 2002-05-30 | Kenneth Jacobs | Secreted proteins and polynucleotides encoding them |
| ATE440865T1 (de) | 1998-03-26 | 2009-09-15 | Univ Leland Stanford Junior | Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region |
| US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
| US20030166047A1 (en) | 1999-05-06 | 2003-09-04 | Millennium Pharmaceuticals, Inc. | Lgr6 nucleic acids and uses thereof |
| WO2001007611A2 (en) | 1999-07-26 | 2001-02-01 | Genentech, Inc. | Novel polynucleotides and method for the use thereof |
| CA2399776A1 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US6824973B2 (en) | 2000-02-03 | 2004-11-30 | Kirin Beer Kabushiki Kaisha | Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide |
| JP4813734B2 (ja) | 2000-03-31 | 2011-11-09 | ザ ジェネラル ホスピタル コーポレイション | 毛の成長を調節する方法 |
| AU5904101A (en) | 2000-04-05 | 2001-10-23 | Hyseq Inc | Methods and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides |
| EP1156062A1 (en) | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Immunomodulatory human MHC class II antigen-binding peptides/proteins |
| AU2001263006A1 (en) | 2000-05-18 | 2001-11-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| AU2001281791A1 (en) | 2000-05-30 | 2001-12-11 | Bayer Aktiengesellschaft | Regulation of human lgr4-like g protein-coupled receptor |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US6768004B2 (en) * | 2001-01-11 | 2004-07-27 | Mueller Sybille | Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies |
| US20040077048A1 (en) | 2002-01-30 | 2004-04-22 | Warren Bridget A. | Protein modification and maintenance molecules |
| US20100292155A1 (en) | 2001-03-05 | 2010-11-18 | Arca Biopharma, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| US20030032034A1 (en) | 2001-03-05 | 2003-02-13 | Tang Y. Tom | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| US7411052B2 (en) | 2001-03-05 | 2008-08-12 | Nuvelo, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| JP4251983B2 (ja) | 2001-06-11 | 2009-04-08 | 協和発酵キリン株式会社 | 造血幹細胞または造血前駆細胞の増殖または生存を支持し得るポリペプチドおよびそれをコードするｄｎａ |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20030022217A1 (en) | 2001-07-02 | 2003-01-30 | Pe Corporation (Ny) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| EP1427747B1 (en) | 2001-08-30 | 2012-04-11 | ARCA biopharma, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| JP2005514917A (ja) | 2001-10-03 | 2005-05-26 | インサイト・ゲノミックス・インコーポレイテッド | 分泌タンパク質 |
| US20040197778A1 (en) | 2002-12-26 | 2004-10-07 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
| US20070237770A1 (en) * | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
| CA2469204A1 (en) | 2001-12-07 | 2003-06-19 | Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
| CA2469941A1 (en) | 2001-12-10 | 2003-07-03 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| CA2483518A1 (en) | 2002-04-26 | 2003-11-06 | Kirin Beer Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same |
| EP1380644A1 (en) | 2002-07-08 | 2004-01-14 | Kylix B.V. | The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| WO2004074436A2 (en) | 2003-02-19 | 2004-09-02 | Incyte Corporation | Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer |
| US20050003405A1 (en) | 2003-04-30 | 2005-01-06 | Hua-Chien Chen | Treatment and diagnostics of cancer |
| KR20060031809A (ko) | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| WO2005110009A2 (en) | 2003-07-22 | 2005-11-24 | Immunex Corporation | COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d |
| DE10339820A1 (de) | 2003-08-22 | 2005-03-17 | Hinzmann, Bernd, Dr. | Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| PT2157192E (pt) | 2003-10-10 | 2013-11-28 | Deutsches Krebsforsch | Composições para diagnóstico e terapia de doenças associadas com a expressão aberrante de futrinas (r-espondinas) |
| WO2005040828A2 (en) | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49) |
| AU2005208945A1 (en) | 2004-01-27 | 2005-08-11 | Kyowa Hakko Kirin Co., Ltd. | Gastrointestinal proliferative factor and uses thereof |
| JP2007526455A (ja) | 2004-02-03 | 2007-09-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法 |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| CA2579142A1 (en) | 2004-09-13 | 2006-03-23 | Macrogenics, Inc. | Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof |
| AU2005318171B2 (en) | 2004-12-20 | 2011-09-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing West Nile virus and uses thereof |
| US7439327B2 (en) | 2005-01-18 | 2008-10-21 | Nuvelo, Inc. | Stem cell factor-like proteins and uses thereof |
| JP2008535853A (ja) | 2005-04-07 | 2008-09-04 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 癌関連遺伝子 |
| JP2009502737A (ja) | 2005-07-26 | 2009-01-29 | キリンファーマ株式会社 | Ｒ−スポンジンを含有する抗腫瘍薬 |
| US7541431B2 (en) | 2005-09-07 | 2009-06-02 | Maine Medical Center | Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto |
| EP1942926A4 (en) | 2005-10-07 | 2010-06-16 | Nuvelo Inc | STEM CELL FACTOR ARTIFICIAL PROTEIN SCFA1 AND ITS USES |
| AU2006308847C1 (en) | 2005-10-31 | 2012-05-10 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| AU2007254853B2 (en) | 2006-06-02 | 2011-11-17 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
| AU2007254942B2 (en) | 2006-06-02 | 2011-10-27 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
| PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| CN101622276B (zh) * | 2006-07-18 | 2015-04-22 | 赛诺菲-安万特 | 用于治疗癌症的抗epha2的拮抗抗体 |
| JP2008044926A (ja) | 2006-08-14 | 2008-02-28 | Trustees Of Columbia Univ In The City Of New York | Ｗｎｔ信号伝達に関係した分泌タンパク質 |
| US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| US8088374B2 (en) | 2006-10-20 | 2012-01-03 | Deutsches Krebsforschungszentrum Stiftung Des Offenlichen Rechts | Methods for inhibition of angiogenesis and vasculogenesis via rspondin antagonists |
| WO2008075796A1 (ja) | 2006-12-21 | 2008-06-26 | Kyowa Hakko Kirin Co., Ltd. | 血球回復促進剤 |
| WO2008088524A2 (en) | 2006-12-28 | 2008-07-24 | Nuvelo, Inc. | Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor |
| CA2691322A1 (en) | 2007-06-12 | 2008-12-24 | Wyeth | Anti-cd20 therapeutic compositions and methods |
| JP5931336B2 (ja) | 2007-07-02 | 2016-06-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんを処置および診断するための組成物および方法 |
| US20120082659A1 (en) | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| WO2009045443A2 (en) | 2007-10-02 | 2009-04-09 | The University Of Rochester | Methods and compositions related to synergistic responses to oncogenic mutations |
| CA2705509A1 (en) | 2007-11-14 | 2009-05-22 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-gpr49 antibody |
| WO2010002862A2 (en) | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| WO2010016766A2 (en) | 2008-08-08 | 2010-02-11 | Koninklijke Nederlandse Akademie Van Wetenschappen | Antibodies recognizing endogenous human lgr5 and/or lgr6 |
| JP5941615B2 (ja) * | 2008-10-31 | 2016-06-29 | 東レ株式会社 | ヒトｃｘｃｌ１タンパク質の免疫学的測定方法 |
| EP2419133A1 (en) | 2009-04-15 | 2012-02-22 | Deutsches Krebsforschungszentrum | Rspondin-3 inhibition in bone disorders |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| US20120165270A1 (en) | 2009-04-27 | 2012-06-28 | Yeon Sook Choi | Inhibition of hair follicle growth by the wnt inhibitor dkk1 |
| WO2010148337A1 (en) | 2009-06-18 | 2010-12-23 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
| WO2011009090A1 (en) * | 2009-07-16 | 2011-01-20 | Xoma Technology Ltd. | Antibodies to high molecular weight melanoma associated antigen |
| CA2772613C (en) | 2009-09-03 | 2020-03-10 | Schering Corporation | Anti-gitr antibodies |
| US20120263730A1 (en) | 2009-12-23 | 2012-10-18 | Deutsches Krebsforschungszentrum | Receptors of rspo2 and rspo3 |
| US8663950B2 (en) | 2010-01-11 | 2014-03-04 | Arizona Board Of Regents | Production of a monoclonal antibody therapeutic against west nile virus in plants |
| US8551715B2 (en) | 2010-02-12 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
| AU2011352167A1 (en) * | 2010-12-28 | 2013-07-11 | Caris Mpi, Inc. | Molecular profiling for cancer |
| GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| HUE034752T2 (en) * | 2011-04-28 | 2018-02-28 | Sbi Biotech Co Ltd | Antibody against human receptor protein tyrosine phosphatase |
| CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
| JP2014530816A (ja) | 2011-10-14 | 2014-11-20 | ノバルティスアーゲー | Ｗｎｔ経路関連疾患のための抗体および方法 |
| US9220774B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of treating cancer by administering anti-GPR49 antibodies |
| WO2013067055A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| EP2812350B1 (en) | 2012-02-11 | 2019-04-03 | F.Hoffmann-La Roche Ag | R-spondin translocations and methods using the same |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| CA2878868A1 (en) | 2012-07-13 | 2014-01-16 | Austin L. Gurney | Rspo3 binding agents and uses thereof |
| CA2905830C (en) | 2013-03-12 | 2022-01-18 | Curegenix Inc. | Quinazoline and naphthyridine derivatives useful in the treatment of cancer |
| WO2014192974A1 (ja) | 2013-05-30 | 2014-12-04 | 株式会社オーダーメードメディカルリサーチ | 抗ｌｇｒ６抗体を含む癌の検出用又は診断用試薬 |
| BR112016008477A2 (pt) | 2013-10-18 | 2017-10-03 | Genentech Inc | Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo |
| US9777052B2 (en) | 2014-12-02 | 2017-10-03 | The Board Of Regents Of The University Of Oklahoma | R-spondin variants, compositions, and methods of use |
| MA41123A (fr) | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
-
2013
- 2013-07-12 CA CA2878868A patent/CA2878868A1/en not_active Abandoned
- 2013-07-12 SG SG11201500233PA patent/SG11201500233PA/en unknown
- 2013-07-12 WO PCT/US2013/050300 patent/WO2014012007A2/en not_active Ceased
- 2013-07-12 NZ NZ704269A patent/NZ704269A/en not_active IP Right Cessation
- 2013-07-12 JP JP2015521849A patent/JP6335896B2/ja not_active Expired - Fee Related
- 2013-07-12 CN CN201380047332.9A patent/CN104854132A/zh active Pending
- 2013-07-12 HK HK15109369.7A patent/HK1208687A1/xx unknown
- 2013-07-12 IN IN350KON2015 patent/IN2015KN00350A/en unknown
- 2013-07-12 KR KR1020157003862A patent/KR20150036603A/ko not_active Ceased
- 2013-07-12 US US13/940,834 patent/US9181333B2/en not_active Expired - Fee Related
- 2013-07-12 EA EA201590144A patent/EA032038B1/ru not_active IP Right Cessation
- 2013-07-12 EP EP13816428.0A patent/EP2872175A4/en not_active Withdrawn
- 2013-07-12 AU AU2013289990A patent/AU2013289990B2/en not_active Ceased
- 2013-07-12 MX MX2015000565A patent/MX2015000565A/es unknown
- 2013-07-12 BR BR112015000776A patent/BR112015000776A2/pt not_active Application Discontinuation
- 2013-07-12 PE PE2015000037A patent/PE20150360A1/es active IP Right Grant
- 2013-07-15 TW TW102125212A patent/TWI636061B/zh not_active IP Right Cessation
- 2013-07-15 TW TW107121349A patent/TW201906861A/zh unknown
- 2013-12-07 UA UAA201500865A patent/UA117659C2/uk unknown
-
2015
- 2015-01-11 IL IL236617A patent/IL236617A0/en unknown
- 2015-01-12 NI NI201500002A patent/NI201500002A/es unknown
- 2015-01-13 PH PH12015500084A patent/PH12015500084A1/en unknown
- 2015-01-13 CL CL2015000097A patent/CL2015000097A1/es unknown
- 2015-02-06 ZA ZA2015/00872A patent/ZA201500872B/en unknown
- 2015-02-12 EC ECIEPI20155280A patent/ECSP15005280A/es unknown
- 2015-09-30 US US14/870,145 patent/US9598497B2/en active Active
-
2017
- 2017-02-22 US US15/439,288 patent/US20170267776A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529641A5 (OSRAM) | ||
| JP2014524746A5 (OSRAM) | ||
| JP6872537B2 (ja) | 抗ｌａｇ３抗体およびその使用 | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| AU2015240599B2 (en) | Humanized antibodies that bind LGR5 | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| CN106573977B (zh) | 针对ceacam1的人源化抗体 | |
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| RU2011115117A (ru) | Нацеленные средства связывания, направленные на dll4, и их применение | |
| JP2016187356A5 (OSRAM) | ||
| JP2010518820A5 (OSRAM) | ||
| JP2013502913A5 (OSRAM) | ||
| JP2014158469A5 (OSRAM) | ||
| JP2010532169A5 (OSRAM) | ||
| JP2018503365A5 (OSRAM) | ||
| JP2016128474A5 (OSRAM) | ||
| JP2013527761A5 (OSRAM) | ||
| JP2014527814A5 (OSRAM) | ||
| JP2012501626A5 (OSRAM) | ||
| RU2018102526A (ru) | Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение | |
| CN109311978B (zh) | Dsg2单克隆抗体和其用途 | |
| JP2012525149A5 (OSRAM) | ||
| JP2015506912A5 (OSRAM) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2012523848A5 (OSRAM) |